Ritholtz Wealth Management trimmed its stake in shares of Indivior PLC (NASDAQ:INDV – Free Report) by 33.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,364 shares of the company’s stock after selling 40,940 shares during the period. Ritholtz Wealth Management owned approximately 0.07% of Indivior worth $2,881,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently made changes to their positions in the stock. Illinois Municipal Retirement Fund grew its position in Indivior by 1.0% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 62,933 shares of the company’s stock worth $2,256,000 after purchasing an additional 611 shares during the period. Pictet Asset Management Holding SA raised its stake in Indivior by 13.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 328,777 shares of the company’s stock valued at $12,017,000 after buying an additional 39,319 shares during the last quarter. Guidance Capital Inc. purchased a new stake in Indivior during the 3rd quarter valued at $782,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Indivior during the 3rd quarter valued at $216,000. Finally, Profund Advisors LLC lifted its holdings in shares of Indivior by 268.8% during the 3rd quarter. Profund Advisors LLC now owns 49,650 shares of the company’s stock valued at $1,780,000 after buying an additional 36,188 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms have recently issued reports on INDV. Barclays raised their price target on Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Wall Street Zen lowered Indivior from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Craig Hallum reiterated a “buy” rating and set a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Finally, Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $46.40.
Read Our Latest Research Report on Indivior
Insider Transactions at Indivior
In other news, CAO Woodrow D. Anderson bought 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares of the company’s stock, valued at $986,400.22. The trade was a 5.74% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.74% of the company’s stock.
Indivior Stock Up 0.2%
Shares of INDV opened at $28.21 on Monday. The business has a 50-day simple moving average of $34.24 and a two-hundred day simple moving average of $35.48. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84. Indivior PLC has a 52 week low of $27.68 and a 52 week high of $42.81.
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. The firm had revenue of $356.00 million for the quarter, compared to the consensus estimate of $329.35 million. On average, equities analysts anticipate that Indivior PLC will post 3.66 earnings per share for the current fiscal year.
Indivior Announces Dividend
The company also recently announced a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were issued a $8.13 dividend. The ex-dividend date of this dividend was Tuesday, November 3rd.
Indivior Profile
Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.
Featured Stories
- Five stocks we like better than Indivior
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
